The prevalence of antiretroviral drug resistance in the United States

AIDS

Volumn 18, Issue 10, 2004, Pages 1393-1401

  Richman, Douglas D ^a,b   Morton, Sally C ^c   Wrin, Terri ^d   Hellmann, Nicholas ^d,f   Berry, Sandra ^c   Shapiro, Martin F ^c,e   Bozzette, Samuel A ^a,b,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

AIDS; Antiretroviral drugs; Drug resistance; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEMOGRAPHY; DRUG SENSITIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; UNITED STATES; VIREMIA; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES;

EID: 3142660152     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131310.52526.c7     Document Type: Article

References (19)

1. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998; 279:1984-1991.
2. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection JAMA 2000; 283:2417-2426.
3. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV infected subjects in North America: a study from the Acute Infection and Early Disease Research Program (AIEDRP). N Engl J Med 2002; 347:385-394.
4. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
5. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003; 37:113-128.
6. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Ther 2000; 5:33-40.
7. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339:1897-1904.
8. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000; 38:2688-2695.
9. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
10. Duan N, McCaffrey DF, Frankel MR, St Clair PA, Beckman R, Keesey JW, et al. HCSUS baseline methods technical report: weighting, imputation and variance estimation. 1999. MR-1060-AHCPR, RAND.(Report)
11. Kish L, Frankel MR. Inference from complex samples. J Royal Stat Soc B 1974; 36:1-37.
12. Stata Statistical Software. College Station: Stata Corporation, 2001.
13. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
14. Wong JK, Hezareh M, Günthard H, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1294.
15. Finzi D, Hermankova M, Pierson T, Carruth LM, Chaisson RE, Quinn TC, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
16. Fleming P, Byers R, Sweeney P, Daniels D, Karon J, Janssen R. HIV prevalence in the United States, 2000. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002 [abstract].
17. Robbins GK, DeGruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
18. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV-1 infection in 2002: updated recommendations of the International AIDS Society USA. JAMA 2002; 288:222-235.
19. Palumbi SR. Humans as the world's greatest evolutionary force. Science 2001; 293:1786-1790.